Evidence map›Paper›PMID 42564915›Full record

ArticleMaterials today. Bio2026

Synergistic nanoparticle dyad improving tumor immunogenicity and reshaping tolerogenic dendritic cells in hepatocellular carcinoma.

Chang Liu, Xiejun Zhao, Hui Song, Yiwen Yuan, Jia Ma, Yingtong Dong, Tianzhao Xu, Xiaojiao Li, Xinghui Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chang LiuDepartment of Clinical Laboratory, Pudong Gongli Hospital, Shanghai University of Medicine&Health Sciences, Shanghai, PR China.
Xiejun ZhaoSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Hui SongDepartment of Clinical Laboratory, Pudong Gongli Hospital, Shanghai University of Medicine&Health Sciences, Shanghai, PR China.
Yiwen YuanDepartment of Clinical Laboratory, Pudong Gongli Hospital, Shanghai University of Medicine&Health Sciences, Shanghai, PR China.
Jia MaSchool of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Yingtong DongBioBank, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, PR China.
Tianzhao XuDepartment of Scientific Research, Pudong Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, PR China.
Xiaojiao LiBioBank, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, PR China.
Xinghui LiuDepartment of Clinical Laboratory, Pudong Gongli Hospital, Shanghai University of Medicine&Health Sciences, Shanghai, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains a global health challenge with limited treatment efficacy despite advances in immune checkpoint blockade (ICB). The low immunogenicity of HCC tumors and impaired dendritic cell (DC) function contribute to suboptimal therapeutic outcomes. To address these limitations, we developed a synergistic nanoparticle dyad combining tumoricidal and immunomodulatory components. Specifically, an anti-GPC3-antibody-conjugated, emodin-loaded spiky mesoporous silica nanoparticle (E-SMSNα) selectively targets HCC cells to induce immunogenic cell death, while a matured DC-membrane-camouflaged, c-di-AMP-loaded nanoparticle (A-MSNm) reprograms dysfunctional DCs, bridging innate and adaptive immunity. This combinatorial approach synergistically promotes antitumor immunity, significantly suppressing primary tumor growth and inducing durable protection against tumor rechallenge. Moreover, it shows strong synergy with PD-1 checkpoint blockade, positioning it as a promising strategy for HCC immunotherapy.

Indexed as

Dendritic cell activationHepatocellular carcinomaNanoparticle dyadTumor immunogenicity

Identifiers

PMID42564915
PMCPMC13446102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.